Alector Inc. (ALEC)
ALEC trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.87
-10.10% on the day
Market cap
$208.8M
Micro cap
Revenue · 2025
$21.0M
-79.1% on 2024
Net income · 2025
-$143.0M
-679.5% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ALEC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001653087 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DELAWARE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $21.0M |
| Net income | -$143.0M |
| Operating income | -$156.0M |
| Net margin | -679.5% |
| Operating margin | -741.3% |
| Revenue growth | -79.1% |
| Cash | $65.8M |
| Total assets | $293.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 9.9× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-07 |
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-10-14 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 621 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PLX | Protalix BioTherapeutics Inc. (DE) | $2.75 | -1.08% | $221.6M |
| LXEO | Lexeo Therapeutics Inc. | $2.74 | -9.87% | $224.8M |
| IVVD | Invivyd Inc. | $0.6460 | -4.05% | $190.4M |
| LCTX | Lineage Cell Therapeutics Inc. | $0.9083 | -4.80% | $229.7M |
| CGEN | Compugen Ltd. | $1.98 | -4.35% | $187.3M |
| STRO | Sutro Biopharma Inc. | $11.01 | -17.09% | $182.6M |
| FATE | Fate Therapeutics Inc. | $2.00 | -6.10% | $239.6M |
| SABS | SAB Biotherapeutics Inc. | $2.68 | -5.30% | $243.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier